Bill & Melinda Gates Foundation

Leinco Technologies is a company that specializes in the development of high-purity monoclonal antibodies, proteins, and various reagents specifically for the diagnostic and biopharmaceutical industries. They provide a range of services, including in vitro antibody and protein production, antibody conjugations, and cell banking. Leinco Technologies focuses on augmenting the early discovery process in life science research and diagnostics, as well as contributing to the innovative development of protein therapeutics. Their expertise in optimizing and adapting products enables clients to effectively meet their research and development needs.

Micron Biomedical is a clinical-stage biopharmaceutical company established in 2014 and located in Atlanta, Georgia. The company focuses on developing microneedle patches specifically for vaccines, including those for influenza and polio. Its innovative microneedle technology aims to improve protective and therapeutic effects while enhancing patient compliance and simplifying the administration process. By leveraging this technology, Micron Biomedical seeks to facilitate the development of effective vaccines, addressing important public health needs.

La Ruche Health provides an innovative platform that connects patients with virtual and at-home healthcare services. Utilizing health AI technology, it offers advice and facilitates the booking of medical services and lab tests through user-friendly applications on iOS, Android, and WhatsApp. The company has recognized WhatsApp as a key distribution channel, being the first to integrate generative AI into this platform to enhance conversational experiences, particularly for low-literacy communities. Additionally, La Ruche Health develops a medical record management system that enables healthcare teams to efficiently manage and exchange medical data through both web and mobile applications. This comprehensive platform allows for virtual and physical consultations, as well as access to a wellness marketplace designed to make modern health services more affordable and accessible to various communities.

ApiJect Systems is a medical technology company focused on revolutionizing the delivery of injectable medications through its innovative platform for prefilled, single-dose injectors. By utilizing medical-grade plastic resin, ApiJect replaces traditional materials like glass and rubber, streamlining the manufacturing process and significantly reducing environmental impact. The ApiJect Platform enables pharmaceutical and biotech companies to efficiently produce scalable prefilled injectors, either on proprietary Blow-Fill-Seal packaging lines or through partnerships with other manufacturers. This approach not only simplifies the supply chain but also accelerates production times, transforming a multi-step process that typically takes weeks into a rapid, efficient operation. Through these advancements, ApiJect aims to make prefilled injections more affordable and accessible to patients globally.

Noze is a leader in digital odor perception technology, creating advanced solutions that replicate the human sense of smell. Their sophisticated digital nose utilizes a specialized sensor, developed with NASA technology, to detect and identify odors in various real-world environments. This technology collects and analyzes data through an AI engine, allowing healthcare providers to assess air quality, monitor chemical footprints, and potentially diagnose diseases based on breath-based odor biomarkers. By enabling real-time disease detection and routine health screenings with a single exhale, Noze aims to enhance human health and well-being while improving patient outcomes.

GE Healthcare is a multinational healthcare company based in Chicago, Illinois, that specializes in manufacturing a diverse range of medical equipment and technologies. Founded in 1892, the company offers products and services including medical imaging, information technologies, medical diagnostics, and patient monitoring systems. GE Healthcare also supports drug discovery and biopharmaceutical manufacturing through intelligent devices and data analytics. The company aims to enhance patient care and outcomes by providing innovative healthcare solutions utilized in hospitals, clinics, research institutions, and pharmaceutical companies globally. By focusing on precision health and digitizing healthcare, GE Healthcare seeks to improve productivity and health outcomes for patients and healthcare providers alike. Additionally, the company pursues an aggressive acquisition strategy to strengthen its presence in emerging markets and expand its life sciences portfolio.

LumiraDx Ltd, incorporated in 2016 and based in London, is a next-generation healthcare company specializing in point-of-care diagnostics. The company manufactures a diagnostic platform designed to provide lab-comparable performance across a wide range of tests, enhancing patient-centered care. LumiraDx aims to simplify and improve diagnostic-led care by offering a compact, portable instrument paired with advanced, low-cost test strips and seamless digital connectivity. Its solutions are focused on achieving healthcare transformation goals by delivering integrated and informed care, resulting in safer, more efficient practices with better patient outcomes. The company operates in multiple countries, including the United States, Italy, Germany, and Sweden, with a significant portion of its revenue generated in the U.S.

Bayer is a global enterprise based in Germany, specializing in life sciences with a strong focus on health care and agriculture. The company develops and commercializes a wide range of products, including pharmaceuticals, consumer health items, and crop science solutions. Bayer's pharmaceutical division offers a variety of medications, while its consumer health segment includes vitamins and food supplements. In agriculture, Bayer provides seeds and crop protection products, including pesticides, herbicides, and fungicides, significantly expanded through the acquisition of Monsanto. Additionally, Bayer is a leader in animal health, contributing to the well-being of both human and animal populations. Overall, Bayer aims to create innovative solutions that address critical challenges in health and nutrition.

Nuvisan Pharma Services is a global provider of product development and support services to the pharmaceutical, biotechnology and medical device industries. We deliver services ranging from a single test to fully integrated drug development programs.

Celanese is a global technology and specialty materials company that engineers and manufactures a diverse range of products essential for everyday living. It is one of the world’s largest producers of acetic acid and its derivatives, which play a crucial role in various industries, including coatings and adhesives. Additionally, Celanese produces specialty polymers utilized in automotive, electronics, medical, building, and consumer markets. The company also manufactures cellulose derivatives, notably used in cigarette filters. With a strong commitment to research and development, Celanese focuses on innovation and provides opportunities for growth and advancement within a performance-driven culture. Its products are integral to the food, beverage, and pharmaceutical industries, reflecting the company's broad impact on daily life.

CaliberMRI is a platform that includes brain, breast, prostate, and custom phantoms, and companion automated quality control software. They provide services that include quantitative MRI, qmri, phantoms, quantitative medicine, radiology, breast cancer, and calibration.

Butterfly Network develops innovative medical imaging devices designed to enhance point-of-care ultrasound programs in hospitals and healthcare organizations. Founded in 2011 and based in Guilford, Connecticut, the company has created the first handheld, single-probe whole-body ultrasound system, utilizing its patented Ultrasound-on-Chip technology. This compact device enables healthcare professionals to perform diagnostic imaging across various medical fields, including cardiology, urology, and obstetrics, all while integrating seamlessly into clinical workflows through mobile applications. Butterfly Network aims to democratize access to medical imaging, particularly for the 4.7 billion individuals globally who currently lack access to ultrasound, thereby promoting early detection and remote management of health conditions.

Ilara Health, founded in 2018 and headquartered in Nairobi, Kenya, focuses on enhancing healthcare access in rural Africa by developing and distributing AI-powered diagnostic devices. These compact devices are designed for primary care doctors in peri-urban and rural clinics, providing accurate and affordable diagnostic services. Ilara Health integrates its technology within a proprietary platform that connects to an electronic medical record system, allowing healthcare providers to efficiently record and manage patient data. By leveraging existing healthcare infrastructure, Ilara Health aims to improve the accessibility and affordability of diagnostic services in underserved regions.

Qloudlab is a pioneering company known for inventing the world's first touchscreen-based biosensor. The company has developed Sceptre, a modular platform that enables multiple diagnostics at the Point-of-Care through a single, mobile device capable of conducting various tests, including blood, urine, saliva, and skin analyses. This innovative technology bridges the gap between smartphones, healthcare, and cloud solutions, offering a cost-effective approach to diagnostics. Complementing this, Loop Medical focuses on revolutionizing blood collection by providing a needleless, pain-free technology. This device collects blood samples using a proprietary cartridge that integrates seamlessly with standard laboratory processes, enhancing the convenience for both patients and healthcare professionals. Together, these innovations represent a significant advancement in accessible and efficient medical diagnostics.

Butterfly Network develops innovative medical imaging devices designed to enhance point-of-care ultrasound programs in hospitals and healthcare organizations. Founded in 2011 and based in Guilford, Connecticut, the company has created the first handheld, single-probe whole-body ultrasound system, utilizing its patented Ultrasound-on-Chip technology. This compact device enables healthcare professionals to perform diagnostic imaging across various medical fields, including cardiology, urology, and obstetrics, all while integrating seamlessly into clinical workflows through mobile applications. Butterfly Network aims to democratize access to medical imaging, particularly for the 4.7 billion individuals globally who currently lack access to ultrasound, thereby promoting early detection and remote management of health conditions.

Scripps Research is a prominent independent, not-for-profit organization dedicated to advancing biomedical research aimed at enhancing human health. Established from the Scripps Metabolic Clinic in 1924, it has grown into one of the largest institutions of its kind, employing around 3,000 individuals across its campuses in La Jolla, California, and Jupiter, Florida. The institute is recognized for its significant contributions to the biomedical sciences, including the development of new treatments for various diseases such as cancer, rheumatoid arthritis, and hemophilia. Scripps Research is home to renowned scientists, including three Nobel laureates, who engage in cutting-edge research. Additionally, its graduate program in biology and chemistry is highly regarded, consistently ranking among the top ten programs in the United States.

NemoCare is developing the smartest and most comprehensive patient monitoring and management system. It is an innovative, continuous vital sign data acquisition, analysis and prediction engine that combines unobtrusive wireless wearable sensors and networks, analytical algorithms and big data to provide affordable continuous, high resolution monitoring for all newborns in hospital, and at home. We use design thinking principles to build life-saving technologies that will transform the way healthcare is delivered. Our current area of work is in newborn and maternal care.

Ventria Bioscience is a privately held biopharmaceutical company with a product pipeline enabled by ExpressTec. ExpressTec is a patented, plant-based recombinant protein manufacturing technology that delivers a ten-fold higher recombinant protein yield than other plant-based systems. Ventria Bioscience's platform technology delivers meaningful and sustainable economic advantages by enabling new product opportunities that were not previously available. It can be used to develop new biotherapeutics, novel vaccines, reagents for biomanufacturing, and industrial and biofuel enzymes.

Qloudlab is a pioneering company known for inventing the world's first touchscreen-based biosensor. The company has developed Sceptre, a modular platform that enables multiple diagnostics at the Point-of-Care through a single, mobile device capable of conducting various tests, including blood, urine, saliva, and skin analyses. This innovative technology bridges the gap between smartphones, healthcare, and cloud solutions, offering a cost-effective approach to diagnostics. Complementing this, Loop Medical focuses on revolutionizing blood collection by providing a needleless, pain-free technology. This device collects blood samples using a proprietary cartridge that integrates seamlessly with standard laboratory processes, enhancing the convenience for both patients and healthcare professionals. Together, these innovations represent a significant advancement in accessible and efficient medical diagnostics.

Atomo Diagnostics was established to capitalize on a core belief that health care products offering significantly improved levels of convenience, simplicity and user experience are disproportionately disruptive and have the potential to be very successful commercial market entrants. Having identified the usability challenges and in-field limitations of existing RDT products, Atomo worked closely with healthcare workers and consumers in a range of settings and determined that by integrating all the test components into a streamlined, end-to-end solution it could significantly improve safety and accuracy and reduce user error rates. This focus on usability and how end users interact with the RDT is one of the key aspects that sets Atomo apart from its competition in the POCT market. Its unique design and patented features mean that AtomoRapid™ addresses and eliminates the vast majority of user errors identified as impacting the performance of standard RDTs in the field. AtomoRapid™ makes it easy to convert proven diagnostic technologies into user-friendly products that deliver unmatched customer satisfaction and in-field performance. These products are successful due to their ability to materially improve usability, convenience, and reliability for both professional and home users. It is this unswerving focus on exceeding user expectations that the management team has applied to the diagnostic market; a market that has to date seen little user-centric innovation. Atomo Diagnostics is headquartered in Sydney, Australia, with corporate offices located in South Africa the UK. The company is led by an executive team with a track record of success commercializing disruptive healthcare products, and the company has assembled an experienced and committed international management team and Board and advisors.

Takeda Pharmaceutical Company Limited is a global biopharmaceutical leader that focuses on researching, developing, manufacturing, and marketing innovative medicines. The company specializes in a range of therapeutic areas, including oncology, gastroenterology, neuroscience, and rare diseases. With its commitment to improving patient outcomes, Takeda is dedicated to delivering advanced pharmaceuticals and therapeutics, as well as vaccines. Founded in 1781 and headquartered in Japan, Takeda operates worldwide, with significant research and development facilities in locations such as Cambridge, Massachusetts, and San Diego, California. The company also engages in strategic investments through its venture capital arm, which supports early-stage companies and technologies that align with its therapeutic focus, fostering collaborations that leverage its extensive R&D capabilities. Takeda's mission is to enhance the quality of life for patients globally through continuous innovation and excellence in healthcare.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on developing innovative vaccines using its proprietary Multiple Antigen Presenting System (MAPS) technology. This approach allows for the combination of protective polysaccharides and proteins into a single vaccine, thereby enhancing immune responses against a variety of infectious diseases affecting both children and adults. Affinivax targets several significant pathogens, including Streptococcus pneumoniae, bacterial nosocomial infections, Salmonella typhi, and Staphylococcus aureus. The company aims to create vaccines that not only provide broader disease coverage compared to existing options but also address infectious diseases lacking effective immunization strategies. Founded in 2014, Affinivax benefits from the expertise of leading professionals in infectious diseases and vaccines, and it has received backing from the Bill & Melinda Gates Foundation, along with an exclusive license from Boston Children’s Hospital for its MAPS technology.

CureVac is a clinical-stage biopharmaceutical company based in Germany, focused on developing vaccines and therapies utilizing messenger RNA (mRNA). Founded in 2000, the company’s innovative approach involves using mRNA as a data carrier to instruct the body to produce proteins that can combat various diseases. CureVac's pipeline includes novel mRNA-based cancer immunotherapies, prophylactic vaccines for infectious diseases, and molecular therapies aimed at enhancing the body’s production of therapeutic proteins. Its most advanced candidate, CV9104, is currently in Phase IIb clinical trials for prostate cancer treatment. Additionally, CureVac has collaborated with GSK to create second-generation vaccines for seasonal influenza and COVID-19, as well as an avian influenza vaccine, while exploring other mRNA vaccine applications in oncology and various therapeutic areas.

CureVac is a clinical-stage biopharmaceutical company based in Germany, focused on developing vaccines and therapies utilizing messenger RNA (mRNA). Founded in 2000, the company’s innovative approach involves using mRNA as a data carrier to instruct the body to produce proteins that can combat various diseases. CureVac's pipeline includes novel mRNA-based cancer immunotherapies, prophylactic vaccines for infectious diseases, and molecular therapies aimed at enhancing the body’s production of therapeutic proteins. Its most advanced candidate, CV9104, is currently in Phase IIb clinical trials for prostate cancer treatment. Additionally, CureVac has collaborated with GSK to create second-generation vaccines for seasonal influenza and COVID-19, as well as an avian influenza vaccine, while exploring other mRNA vaccine applications in oncology and various therapeutic areas.

YourBio Health is focused on revolutionizing the blood sampling and testing process to enhance the interaction between diagnostic medicine and healthcare consumers. The company has developed a blood collection device that allows for convenient and virtually painless blood testing. Utilizing its proprietary Touch Activated Phlebotomy (TAP) technology, the device enables users to collect blood from their upper arm with a simple push of a button, facilitating easy and rapid diagnostic testing in various settings. This innovative approach aims to eliminate barriers in acquiring critical diagnostic information, thereby promoting informed healthcare delivery and empowering patients to take an active role in their well-being. By integrating TAP technology with a range of diagnostic assays, YourBio Health seeks to improve both patient and clinician experiences in the healthcare landscape.